fbpx
Donate Toggle Menu

Program-At-A-Glance

Friday, 21 April 2023

8:30WELCOME SESSION AND SESSION 1: [SURGICAL]Lars Lund
Bradley Leibovich
Region Syddanmark
Mayo Clinic
Treatment Debate Localized Disease: A: Introduction of Active Surveillance vs. TherapySarah PsutkaUW
Treatment Debate Localized Disease: B: Surgical options for localized diseasePernilla SundqvistRegion Örebro
The risks and benefits of neoadjuvant therapy in locally advanced RCCGrant StewartUniversity of Cambridge
Results from Adjuvant Trials: how to select patients and therapiesViktor GrünwaldUniversität Essen
Surgery in primary metastatic disease: who, how, when?Arnaud MejeanHôpital Européen Georges-Pompidou
10:15SESSION 2: [PATHOLOGY]Samra Turajlic
Elizabeth (Lisa) Henske
The Institute of Cancer Research
Brigham & Women’s, Harvard Medical School
WHO pathological classification: Present and FutureFerran Algaba ArreaFundació Puigvert
AI/Digital PathologyPayal KapurUT Southwestern
Epigenetic regulation of oncogenic signaling in RCCJessica DownsThe Institute of Cancer Research
Developing accurate mouse models of ccRCCAri HakimiMemorial Sloan Kettering Cancer Center
Understanding non-clear cell molecular pathologyElizabeth (Lisa) HenskeBrigham & Women’s, Harvard Medical School
Sarcomatoid and Rhadoid Subtypes and clinical implicationsBradley LeibovichMayo Clinic
11:30Keynote IRobert JonesBeatson West of Scotland Cancer Centre
11:45SESSION 3: CARING FOR THE WHOLE PATIENT: NON CLINICAL CONSIDERATIONSMichael Staehler
Cristina Suárez
Ludwig-Maximilians University of Munich
Vall d’Hebron Hospital Universitari
Living with RCC – long term survival and frustrationTheresa JunkerRegion Syddanmark
Supplements and Concomitant Drugs – Interactions, EfficacyDora Niedersüß-Beke​Wilhelminenspital Vienna
Patients trust in careDena BattleKCCure
Quality of life – what is that and how can we optimize it?David CellaNorthwestern Medicine-Feinberg School of Medicine
Rare subtypes – a patients talePer LarsenRetired chief of police – patient
12:45POSTERS AND LUNCH
13:00Industry Session
14:15 SESSION 4: ORAL ABSTRACTSGabriel Malouf
Lars Lund
Institut de Cancérologie de Strasbourg & IGBMC
Region Syddanmark
15:30SESSION 5: TREATMENT DEBATES FIRST LINE THERAPYViktor Grünwald
Lisa Pickering
Universitäts­klinikum Essen
Royal Marsden NHS Foundation Trust
IO-TKI 2blets vs IO-TKI 3plets Debate (3plet presenter)Tian ZhangUTSW
IO-TKI 2blets vs IO-TKI 3plets Debate (2blet presenter)Laurence AlbigesGustave Roussy Cancer Campus
IO-IO DebateMike AtkinsGeorgetown-Lombardi Comprehesive Cancer Center
Illustrative Clinical scenarios of ea above (wrap up info)Lisa PickeringRoyal Marsden NHS Foundation Trust
Optimal toxicity management in an era of increasing doublet and triplet therapies.Kate YoungRoyal Marsden NHS Foundation Trust
16:30 KEYNOTE II: AWARDS
16:55WOMEN IN RCC (SPONSORED SESSION)Laurence Albiges
Lisa Pickering
Gustave Roussy Cancer Campus
Royal Marsden NHS Foundation Trust
17:55 RECEPTION
18:15Poster WalkIgnacio Duran
Tim O’Brien
Universidad Tecnológica Metropolitana
Guy’s and St Thomas’ NHS Foundation Trust

Saturday, 22 April 2023

8:30WELCOME SESSION AND SESSION 6: KCA UPDATESDan George
Dora Niedersüß-Beke
Duke University Medical Center
​Wilhelminenspital Vienna
KCA Updates
KEYNOTE III (Award Winners)
9:00SESSION 7: BEYOND SECOND LINE THERAPYLaurence Albiges
Dan George
Gustave Roussy Cancer Campus
Duke University Medical Center
Criteria to select further lines of therapies after IO-IO 1st lineUlka VaishampayanUniversity of Michigan
How to select further line therapies and why after IO-TKI 1st lineIgnacio DuranUniversidad Tecnológica Metropolitana
Integrating predictive biomarkers into therapy selectionGabriel Malouf
Institut de Cancérologie de Strasbourg & IGBMC
Oxford debate on optimizing later line therapy selectionCamillo PortaSan Matteo University Hospital
10:05 SESSION 8 – MANAGEMENT OF RCCSylvie Negrier
Ulka Vaishampayan
UNICANCER
University of Michigan
Future radiotherapy optionsRaquib HannanUT Southwestern Medical Center
Staging and Restaging of RCC and mRCCDaniel HengTom Baker Cancer Center
Modern PET ImagingLena UnterrainerResident, LMU Munich
11:15SESSION 9 – NON CLEAR CELL RCCCristina Suárez
Mike Atkins
Vall d’Hebron Hospital Universitari
Georgetown-Lombardi Comprehesive Cancer Center
Papillary RCCManuela SchmidingerAKH Wien
CDC, RMC
Giuseppe Procopio

Istituto Nazionale dei Tumori
Treatment of molecularly defined metastatic RCCStéphane OudardAP-HP. Centre – Université de Paris – HEGP Hôpital Européen Georges Pompidou
Role of IO in non-clear RCCNizar TannirUT MD Anderson Cancer Center
12:15 Lunch and Posters
12:30 Industry Session
13:45SESSION 10: BASIC SCIENCE INTEGRATED INTO THERAPEUTIC MANAGEMENTAnnika Fendler
Elizabeth (Lisa) Henske
Crick Institue
Brigham & Women’s, Harvard Medical School
TLS and B-cell responses in RCCFlorent PetitprezThe University of Edinburgh
Circulating T cell activation as predictor of therapy responseHaydn KissickEmory University
Patient-derived organotypic cultures predict immunotherapy responsesMarieta TomaUniversity Hospital Bonn
Heterogeneity in TranscriptomicsAnnika FendlerCrick Institute
Optimizing clinical trial designs by integrating tissue derived markersSamra TurajlicThe Institute of Canceer Research
14:45SESSION 11: SPECIAL TOPICSSylvie NegrierUNICANCER
Gut microbiome to influence IO responseNazli DizmanYale University
HIF2a in VHL and beyondTian ZhangUT Southwest
Novel therapeutics *except HiF2aThomas PowlesNHS Barts Health
Therapy of patients with and of brain metastasesSylvie NegrierUNICANCER
15:40POSTER AWARD PRESENTATIONLisa Pickering
Lars Lund
Royal Marsden NHS Foundation Trust
Region Syddanmark
15:50WOODFIREMichael StaehlerLudwig-Maximilians University of Munich
Bradley LeibovichMayo Clinic
Ulka VaishampayanUniversity of Michigan
Arnaud MejeanHôpital Européen Georges-Pompidou
Thomas PowlesNHS Barts Health
16:50SESSION CLOSINGMichael StaehlerLudwig-Maximilians University of Munich
Gabriel MaloufInstitut de Cancérologie de Strasbourg & IGBMC